Unfortunately, if I explained this in technical terms, most loyal readers would swoon. But in layperson's terms, the great news about the mRNA approach to vaccination is its adaptability to variant strains of what it is vaccinating against. In short, both the safety and efficacy clinical trials to deal with a variant can be shortened dramatically and the additional protection be given by an add-on booster shot.
No comments:
Post a Comment